Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Top Midday Gainers

Top Midday Gainers

MT newswireMT newswire2026/10/05 17:58

01:58 PM EDT, 10/05/2026 (MT Newswires) -- WISeSat.Space (SAIQ) shares soared 260% amid heavy trading after the company, a subsidiary of WISeKey (WKEY), completed its business combination with Columbus Acquisition on Friday. More than 55.4 million shares of WISeSat.Space traded intraday compared with a daily average of about 138,000. Veea (VEEA) received unsecured loans totaling $1.65 million from NLabs, a principal stockholder and an affiliate of its chief executive officer, the company said in a regulatory filing Friday. Veea shares surged 50% as intraday trading volume climbed to over 45.2 million, versus a daily average of roughly 5.56 million. Vaxcyte (PCVX) said its experimental VAX-31 drug candidate met all pre-specified primary endpoints across age groups studied, compared with Prevnar 20 and/or Capvaxive, in a phase 3 trial of the invasive pneumococcal disease and pneumococcal pneumonia treatment. Shares jumped 30%, with intraday trading volume at 10.6 million versus a daily average of about 1.15 million. Price: 6.86, Change: +5.01, Percent Change: +270.81

01:58 PM EDT, 10/05/2026 (MT Newswires) -- WISeSat.Space (SAIQ) shares soared 260% amid heavy trading after the company, a subsidiary of WISeKey (WKEY), completed its business combination with Columbus Acquisition on Friday. More than 55.4 million shares of WISeSat.Space traded intraday compared with a daily average of about 138,000. Veea (VEEA) received unsecured loans totaling $1.65 million from NLabs, a principal stockholder and an affiliate of its chief executive officer, the company said in a regulatory filing Friday. Veea shares surged 50% as intraday trading volume climbed to over 45.2 million, versus a daily average of roughly 5.56 million. Vaxcyte (PCVX) said its experimental VAX-31 drug candidate met all pre-specified primary endpoints across age groups studied, compared with Prevnar 20 and/or Capvaxive, in a phase 3 trial of the invasive pneumococcal disease and pneumococcal pneumonia treatment. Shares jumped 30%, with intraday trading volume at 10.6 million versus a daily average of about 1.15 million. Price: 6.86, Change: +5.01, Percent Change: +270.81
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned

According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

智通财经•2026/11/09 11:09
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned

SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries